Author
NHD Technical Team
NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.
-
Quality & Documentation
Peptide Storage vs Shipping Excursions: What Stability Data Can Actually Support
-
Evidence Reviews
5-Amino-1MQ and NNMT Inhibition: What the Preclinical Evidence Actually Shows
-
Evidence Reviews
How to Verify 5-Amino-1MQ Research Material: Identity, Purity and Lot Documentation
-
Evidence Reviews
Tirzepatide Dual GIP/GLP-1 Signaling: Mechanism and Trial Endpoints Explained
-
Evidence Reviews
Tirzepatide in 2026: Approved Drug Evidence vs Research-Use Material
-
Evidence Reviews
Retatrutide Triple Agonism: What the Phase 2 Trial Found—and Did Not Prove
-
Evidence Reviews
Retatrutide Development Status in 2026: An Evidence Map for Researchers
-
Evidence Reviews
Cagrilintide as a Long-Acting Amylin Analog: Reading the Phase 2 Evidence
-
Evidence Reviews
Cagrilintide vs CagriSema: Molecules, Trial Evidence and Common Mix-Ups
-
Evidence Reviews
Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured
-
Evidence Reviews
Tesamorelin Research Material vs EGRIFTA WR: Why Formulation and Status Matter
-
Evidence Reviews
BPC-157 + TB-500 in the 2026 Rat Achilles Tendon Study: A Close Reading